GEL4MED, INC.
Brighton, MA · Medtech · Private
Self-assembly peptide-based matrix (G4Derm) for antimicrobial wound care and tissue regeneration
- Grants
- $14M
- 19 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 21
- 0 granted · 21 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2015201720192021202320252027
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Flowable antimicrobial skin scaffolding matrix that promotes regeneration | $223,369 | |
| Federal grant | Department of Health and Human Services · Phase I · Surgical Wound Closure Matrices for the Prevention of Superficial Incisional SSI | $223,866 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutic cells encapsulation and delivery for improved healing of chronic diabetic wounds | $298,530 | |
| Federal grant | Department of Health and Human Services · Phase I · Management of bioburden and tissue regeneration in diabetic wounds using engineered matrices | $292,475 | |
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Tunable Mechanical and Functional Properties of Peptide Films | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel dermal templates for prevention and treatment of biofilms in cutaneous wounds | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Antimicrobial dermal matrices to promote infection free wound closure in cutaneous wounds | $348,852 | |
| Federal grant | Department of Health and Human Services · Phase II · Antimicrobial dermal matrices to promote infection free wound closure in cutaneous wounds | $1,699,924 | |
| Federal grant | Department of Health and Human Services · Phase II · TABA funding for the Fast Track project "ANTIMICROBIAL DERMAL MATRICES TO PROMOTE INFECTION FREE WOUND CLOSURE IN CUTANEOUS WOUNDS_R44GM133305" | $2,730,017 | |
| Federal grant | Department of Health and Human Services · Phase I · Treatment of microbial keratitis and corneal wound healing | $380,007 | |
| Federal grant | Department of Health and Human Services · Phase I · Antifungal Dermal Templates for Wound Healing | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Treatment of microbial keratitis and corneal wound healing | $29,697 | |
| Federal grant | Department of Health and Human Services · Phase II · Antimicrobial dermal matrices to promote infection free wound closure in cutaneous wounds | $980,093 | |
| Federal grant | Department of Health and Human Services · Phase II · TABA funding for the Fast Track project "ANTIMICROBIAL DERMAL MATRICES TO PROMOTE INFECTION FREE WOUND CLOSURE IN CUTANEOUS WOUNDS_R44GM133305" | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Antimicrobial dermal matrices to promote infection free wound closure in DTU-DFUs. | $1,119,996 | |
| Federal grant | Department of Health and Human Services · Phase II · Antimicrobial dermal matrices to promote infection free wound closure in cutaneous wounds | $1,200,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Antimicrobial dermal matrices to promote infection free wound closure in DTU-DFUs. | $1,529,428 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel dermal templates for prevention and treatment of biofilms in cutaneous wounds | $1,050,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel dermal templates for prevention and treatment of biofilms in cutaneous wounds | $1,000,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2096 | FOLI BIO INC. | — | — |
| 2097 | InseRT | — | — |
| 2098 | Monogram Orthopaedics Inc. | — | — |
| 2099 | GEL4MED, INC. | — | — |
| 2100 | EXVADE BIOSCIENCE INC | — | — |
| 2101 | NEUROFIELDZ INC. | — | — |
| 2102 | AI Viewlife | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Delivery Of Cells And Tissues With Self-assembling Peptide Hydrogel Materialsapplication
- Self-assembling Amphiphilic Peptide Hydrogels For Treatment Of Nerve Injuryapplication
- Films Formed From Self-assembling Peptide Hydrogelsapplication
- Self-assembling Amphiphilic Peptide Hydrogelsapplication
- Antimicrobial Matrix Formed From Peptide Hydrogelsapplication
- Antifungal Matrix Formed From Peptide Hydrogelsapplication
- Topical And Parenteral Use And Administration Of Self-assembling Amphiphilic Peptide Hydrogelsapplication
- Topical And Parenteral Use And Administration Of Self-assembling Amphiphilic Peptide Hydrogelsapplication
- Antifungal Matrix Formed From Peptide Hydrogelsapplication
- Delivery Of Cells And Tissues With Self-assembling Peptide Hydrogel Materialsapplication
- Self-assembling Amphiphilic Peptide Hydrogelsapplication
- Topical And Parenteral Use And Administration Of Self-assembling Amphiphilic Peptide Hydrogelsapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.